Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 479 in Relapsed/Refractory EFT and DSRCT
NCT00563680Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 2007
- Primary completion
- Aug 2009
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ganitumab in Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), sponsored by ImmunityBio, Inc.. Started Oct 2007; status: completed.
02
Drugs
ganitumab
03
Conditions
Ewing sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT00563680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00563680.